JB Bass Jr, LS Farer, PC Hopewell, R O'Brien, RF Jacobs, F Ruben, DE Snider Jr and G Thornton

Treatment of Tuberculosis. 1. A 6-mo regimen consisting of isoniazid, rifampin, and pyrazinamide given for 2 mo followed by isoniazid and rifampin for 4 mo is the preferred treatment for patients with fully susceptible organisms who adhere to treatment. Ethambutol (or streptomycin in children too young to be monitored for visual acuity) should be included in the initial regimen until the results of drug susceptibility studies are available, unless there is little possibility of drug resistance (i.e., there is less than 4% primary resistance to isoniazid in the community, and the patient has had no previous treatment with antituberculosis medications, is not from a country with a high prevalence of drug resistance, and has no known exposure to a drug-resistant case). This four-drug, 6-mo regimen is effective even when the infecting organism is resistant to INH. This recommendation applies to both HIV-infected and uninfected persons. However, in the presence of HIV infection it is critically important to assess the clinical and bacteriologic response. If there is evidence of a slow or suboptimal response, therapy should be prolonged as judged on a case by case basis. 2. Alternatively, a 9-mo regimen of isoniazid and rifampin is acceptable for persons who cannot or should not take pyrazinamide. Ethambutol (or streptomycin in children too young to be monitored for visual acuity) should also be included until the results of drug susceptibility studies are available, unless there is little possibility of drug resistance (see Section 1 above). If INH resistance is demonstrated, rifampin and ethambutol should be continued for a minimum of 12 mo. 3. Consideration should be given to treating all patients with directly observed therapy (DOT). 4. Multiple-drug- resistant tuberculosis (i.e., resistance to at least isoniazid and rifampin) presents difficult treatment problems. Treatment must be individualized and based on susceptibility studies. In such cases, consultation with an expert in tuberculosis is recommended. 5. Children should be managed in essentially the same ways as adults using appropriately adjusted doses of the drugs. This document addresses specific important differences between the management of adults and children. 6. Extrapulmonary tuberculosis should be managed according to the principles and with the drug regimens outlined for pulmonary tuberculosis, except for children who have miliary tuberculosis, bone/joint tuberculosis, or tuberculous meningitis who should receive a minimum of 12 mo of therapy.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				J. J. Wilkins, R. M. Savic, M. O. Karlsson, G. Langdon, H. McIlleron, G. Pillai, P. J. Smith, and U. S. H. Simonsson Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2138 - 2148. [Abstract] [Full Text] [PDF]

				A. Kwara, J. S. Herold, J. T. Machan, and E. J. Carter Factors Associated With Failure To Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island Chest, April 1, 2008; 133(4): 862 - 868. [Abstract] [Full Text] [PDF]

				S. C. Ngo, O. Zimhony, W. J. Chung, H. Sayahi, W. R. Jacobs Jr., and J. T. Welch Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2430 - 2435. [Abstract] [Full Text] [PDF]

				M. Singh, K. Kothur, D. Dayal, and S. Kusuma Perinatal Tuberculosis a Case Series J Trop Pediatr, April 1, 2007; 53(2): 135 - 138. [Abstract] [Full Text] [PDF]

				N. Schonfeld The mycobacterial mystery Eur. Respir. J., December 1, 2006; 28(6): 1076 - 1078. [Full Text] [PDF]

				Y. J. Ryu, H. Kim, C. M. Yu, J. C. Choi, Y. S. Kwon, and O. J. Kwon Use of silicone stents for the management of post-tuberculosis tracheobronchial stenosis Eur. Respir. J., November 1, 2006; 28(5): 1029 - 1035. [Abstract] [Full Text] [PDF]

				R. Erbes, K. Oettel, M. Raffenberg, H. Mauch, M. Schmidt-Ioanas, and H. Lode Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care Eur. Respir. J., June 1, 2006; 27(6): 1223 - 1228. [Abstract] [Full Text] [PDF]

				B. J. Marais, R. P. Gie, H. S. Schaaf, N. Beyers, P. R. Donald, and J. R. Starke Childhood Pulmonary Tuberculosis: Old Wisdom and New Challenges Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1078 - 1090. [Abstract] [Full Text] [PDF]

				D.-H. Han, J.-W. Song, H.-S. Chung, and J.-H. Lee Resolution of Residual Pleural Disease According to Time Course in Tuberculous Pleurisy During and After the Termination of Antituberculosis Medication Chest, November 1, 2005; 128(5): 3240 - 3245. [Abstract] [Full Text] [PDF]

				W-J. Koh, O. J. Kwon, Y. K. Park, W. J. Lew, and G. H. Bai Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis Eur. Respir. J., September 1, 2005; 26(3): 557 - 557. [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, S. Shepherd, J. McLarty, L. Griffith, and R. J. Wallace Jr. Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 250 - 253. [Abstract] [Full Text] [PDF]

				W. L. Risser and K. Connelly Smith Tuberculosis in Incarcerated Youth in Texas JAMA, June 8, 2005; 293(22): 2716 - 2717. [Full Text] [PDF]

				N Cranswick and K Mulholland Isoniazid treatment of children: can genetics help guide treatment? Arch. Dis. Child., June 1, 2005; 90(6): 551 - 553. [Full Text] [PDF]

				M. Sen, D. Gregson, and J. Lewis Neonatal exposure to active pulmonary tuberculosis in a health care professional Can. Med. Assoc. J., May 24, 2005; 172(11): 1453 - 1456. [Abstract] [Full Text] [PDF]

				J. A. Caminero Management of multidrug-resistant tuberculosis and patients in retreatment Eur. Respir. J., May 1, 2005; 25(5): 928 - 936. [Abstract] [Full Text] [PDF]

				C. Perez-Guzman, M. H. Vargas, F. Quinonez, N. Bazavilvazo, A. Aguilar, and the Instituto Nacional de Enfermedades Respiratori A Cholesterol-Rich Diet Accelerates Bacteriologic Sterilization in Pulmonary Tuberculosis Chest, February 1, 2005; 127(2): 643 - 651. [Abstract] [Full Text] [PDF]

				J. Rozovsky-Weinberger, J. P. Parada, L. Phan, D. G. Droller, M. Deloria-Knoll, J. S. Chmiel, and C. L. Bennett Delays in Suspicion and Isolation Among Hospitalized Persons With Pulmonary Tuberculosis at Public and Private US Hospitals During 1996 to 1999 Chest, January 1, 2005; 127(1): 205 - 212. [Abstract] [Full Text] [PDF]

				R. M. Jasmer, C. B. Seaman, L. C. Gonzalez, L. M. Kawamura, D. H. Osmond, and C. L. Daley Tuberculosis Treatment Outcomes: Directly Observed Therapy Compared with Self-Administered Therapy Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 561 - 566. [Abstract] [Full Text] [PDF]

				T. F. Brewer and S. J. Heymann The Long Journey to Health Equity JAMA, July 14, 2004; 292(2): 269 - 271. [Full Text] [PDF]

				P. Farnia, F. Mohammadi, M. Mirsaedi, A. Z. Zarife, J. Tabatabee, K. Bahadori, M. Bahadori, M. R. Masjedi, and A. A. Velayati Application of Oxidation-Reduction Assay for Monitoring Treatment of Patients with Pulmonary Tuberculosis J. Clin. Microbiol., July 1, 2004; 42(7): 3324 - 3325. [Abstract] [Full Text] [PDF]

				O. Zimhony, C. Vilcheze, and W. R. Jacobs Jr. Characterization of Mycobacterium smegmatis Expressing the Mycobacterium tuberculosis Fatty Acid Synthase I (fas1) Gene J. Bacteriol., July 1, 2004; 186(13): 4051 - 4055. [Abstract] [Full Text] [PDF]

				K. J. Seung, K. Joseph, R. Hurtado, M. Rich, S. Shin, J. Furin, F. Leandre, J. Mukherjee, P. Farmer, and J. A. Caminero Number of Drugs to Treat Multidrug-resistant Tuberculosis Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1336 - 1337. [Full Text] [PDF]

				S. Bhakta, G. S. Besra, A. M. Upton, T. Parish, C. Sholto-Douglas-Vernon, K. J.C. Gibson, S. Knutton, S. Gordon, R. P. daSilva, M. C. Anderton, et al. Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target J. Exp. Med., May 3, 2004; 199(9): 1191 - 1199. [Abstract] [Full Text] [PDF]

				I. Pilate and Y. W. Choi Tuberculous Pleural Effusion [letter] * Dr Choi responds: Radiology, April 1, 2004; 231(1): 283 - 284. [Full Text] [PDF]

				A. M. Mohamed, D. R. Bastola, G. P. Morlock, R. C. Cooksey, and S. H. Hinrichs Temperature-Mediated Heteroduplex Analysis for Detection of pncA Mutations Associated with Pyrazinamide Resistance and Differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by Denaturing High- Performance Liquid Chromatography J. Clin. Microbiol., March 1, 2004; 42(3): 1016 - 1023. [Abstract] [Full Text] [PDF]

				G. Laifer, A. F. Widmer, R. Frei, W. Zimmerli, and U. Fluckiger Polymerase Chain Reaction for Mycobacterium tuberculosis: Impact on Clinical Management of Refugees With Pulmonary Infiltrates Chest, March 1, 2004; 125(3): 981 - 986. [Abstract] [Full Text] [PDF]

				J. A. Caminero, P. de March, and M. D. Iseman Statements of ATS, CDC, and IDSA on Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 316 - 317. [Full Text] [PDF]

				G. P. Morlock, B. Metchock, D. Sikes, J. T. Crawford, and R. C. Cooksey ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3799 - 3805. [Abstract] [Full Text] [PDF]

				R. J. O'Brien Development of Fluoroquinolones as First-line Drugs for Tuberculosis--at Long Last! Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1266 - 1268. [Full Text] [PDF]

				M. F. Hovell, C. L. Sipan, E. J. Blumberg, C. R. Hofstetter, D. Slymen, L. Friedman, K. Moser, N. J. Kelley, and A. Y. Vera Increasing Latino Adolescents' Adherence to Treatment for Latent Tuberculosis Infection: A Controlled Trial Am J Public Health, November 1, 2003; 93(11): 1871 - 1877. [Abstract] [Full Text] [PDF]

				D. Guwatudde, M. Nakakeeto, E. C. Jones-Lopez, A. Maganda, A. Chiunda, R. D. Mugerwa, J. J. Ellner, G. Bukenya, and C. C. Whalen Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda Am. J. Epidemiol., November 1, 2003; 158(9): 887 - 898. [Abstract] [Full Text] [PDF]

				T. K. Marras, J. Wilson, E. E. L. Wang, M. Avendano, and J. W. Yang Tuberculosis Among Tibetan Refugee Claimants in Toronto: 1998 to 2000 Chest, September 1, 2003; 124(3): 915 - 921. [Abstract] [Full Text] [PDF]

				P. A. LoBue and K. S. Moser Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 443 - 447. [Abstract] [Full Text] [PDF]

				P. Cahn, H. Perez, G. Ben, and C. Ochoa Tuberculosis and HIV: A Partnership Against the Most Vulnerable J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2003; 2(3): 106 - 123. [Abstract] [PDF]

				J. Coste and J. Pouchot A grey zone for quantitative diagnostic and screening tests Int. J. Epidemiol., April 1, 2003; 32(2): 304 - 313. [Abstract] [Full Text] [PDF]

				X.-Y. Fan, Z.-Y. Hu, F.-H. Xu, Z.-Q. Yan, S.-Q. Guo, and Z.-M. Li Rapid Detection of rpoB Gene Mutations in Rifampin-Resistant Mycobacterium tuberculosis Isolates in Shanghai by Using the Amplification Refractory Mutation System J. Clin. Microbiol., March 1, 2003; 41(3): 993 - 997. [Abstract] [Full Text] [PDF]

				D. E. Morisky, V. J. Ebin, C. K. Malotte, A. Coly, and G. Kominski Assessment Of Tuberculosis Treatment Completion In An Ethnically Diverse Population Using Two Data Sources: Implications for Treatment Interventions Eval Health Prof, March 1, 2003; 26(1): 43 - 58. [Abstract] [PDF]

				K.-D. K. L. Lessnau and S. Qarah Multidrug-Resistant Tuberculosis in Pregnancy: Case Report and Review of the Literature Chest, March 1, 2003; 123(3): 953 - 956. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				K. Khan, P. Muennig, M. Behta, and J. G. Zivin Global Drug-Resistance Patterns and the Management of Latent Tuberculosis Infection in Immigrants to the United States N. Engl. J. Med., December 5, 2002; 347(23): 1850 - 1859. [Abstract] [Full Text] [PDF]

				E. D Chan and M. D Iseman Current medical treatment for tuberculosis BMJ, November 30, 2002; 325(7375): 1282 - 1286. [Full Text] [PDF]

				R. M. Jasmer, J. J. Saukkonen, H. M. Blumberg, C. L. Daley, J. Bernardo, E. Vittinghoff, M. D. King, L. M. Kawamura, P. C. Hopewell, and for the Short-Course Rifampin and Pyrazinamide for Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial Ann Intern Med, October 15, 2002; 137(8): 640 - 647. [Abstract] [Full Text] [PDF]

				M. Narita, M. Kellman, D. L. Franchini, M. E. McMillan, E. S. Hollender, and D. Ashkin Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients With HIV Infection: The 2-Year Experience of a Comprehensive Community-Based Program in Broward County, Florida Chest, October 1, 2002; 122(4): 1292 - 1298. [Abstract] [Full Text] [PDF]

				B. Smith, M. A K Ryan, G. C Gray, J. M Polonsky, and D. H Trump Tuberculosis infection among young adults enlisting in the United States Navy Int. J. Epidemiol., October 1, 2002; 31(5): 934 - 939. [Abstract] [Full Text] [PDF]

				K. J. Swartzman Latent tuberculosis treatment Can. Med. Assoc. J., September 1, 2002; 167(5): 453 - 454. [Full Text]

				N. N. Bock, T. R. Sterling, C. D. Hamilton, C. Pachucki, Y.-C. Wang, D. S. Conwell, A. Mosher, M. Samuels, and A. Vernon A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1526 - 1530. [Abstract] [Full Text] [PDF]

				M. C. White, J. P. Tulsky, J. Goldenson, C. J. Portillo, M. Kawamura, and E. Menendez Randomized Controlled Trial of Interventions to Improve Follow-up for Latent Tuberculosis Infection After Release From Jail Arch Intern Med, May 13, 2002; 162(9): 1044 - 1050. [Abstract] [Full Text] [PDF]

				T. A. Vannelli, A. Dykman, and P. R. Ortiz de Montellano The Antituberculosis Drug Ethionamide Is Activated by a Flavoprotein Monooxygenase J. Biol. Chem., April 5, 2002; 277(15): 12824 - 12829. [Abstract] [Full Text] [PDF]

				J. Baillargeon, M. Kelley, M. J. Lichtenstein, H. B. Jenson, and L. Linthicum Management of Tuberculosis in the Texas Prison System Journal of Correctional Health Care, April 1, 2002; 9(1): 77 - 93. [Abstract] [PDF]

				H. Geldmacher, C. Taube, C. Kroeger, H. Magnussen, and D. K. Kirsten Assessment of Lymph Node Tuberculosis in Northern Germany* : A Clinical Review Chest, April 1, 2002; 121(4): 1177 - 1182. [Abstract] [Full Text] [PDF]

				A. De Logu, V. Onnis, B. Saddi, C. Congiu, M. L. Schivo, and M. T. Cocco Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis J. Antimicrob. Chemother., February 1, 2002; 49(2): 275 - 282. [Abstract] [Full Text] [PDF]

				Tuberculosis and HIV AIDS Clinical Care, February 1, 2002; 2002(201): 6 - 6. [Full Text]

				S. Leiner, H. M. Blumberg, C. del Rio, L. E. Fantry, P.E. Meissner, J.B.S. Coulter, and P. M. Small Management of Tuberculosis N. Engl. J. Med., November 15, 2001; 345(20): 1501 - 1502. [Full Text] [PDF]

				M. Iseman A 52-Year-Old Man With a Positive PPD JAMA, October 24, 2001; 286(16): 2015 - 2022. [Full Text] [PDF]

				G. H. Mazurek, P. A. LoBue, C. L. Daley, J. Bernardo, A. A. Lardizabal, W. R. Bishai, M. F. Iademarco, and J. S. Rothel Comparison of a Whole-Blood Interferon {gamma} Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium tuberculosis Infection JAMA, October 10, 2001; 286(14): 1740 - 1747. [Abstract] [Full Text] [PDF]

				R. Long, M. Scalcini, and J. Olle-Goig TREATMENT OF TUBERCULOSIS IN HAITI Am J Public Health, October 1, 2001; 91(10): 1546 - 1547. [Full Text] [PDF]

				M. Desvarieux, W. D. Johnson Jr, and J. W. Pape DESVARIEUX ET AL. RESPOND Am J Public Health, October 1, 2001; 91(10): 1547 - 1547. [Full Text] [PDF]

				M. Narita, P. Alonso, M. Lauzardo, E. S. Hollender, A. E. Pitchenik, and D. Ashkin Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994-1997 Chest, August 1, 2001; 120(2): 343 - 348. [Abstract] [Full Text] [PDF]

				A. M. Kanaya, D. V. Glidden, and H. F. Chambers Identifying Pulmonary Tuberculosis in Patients With Negative Sputum Smear Results Chest, August 1, 2001; 120(2): 349 - 355. [Abstract] [Full Text] [PDF]

				R. E. Besser, B. Pakiz, J. M. Schulte, S. Alvarado, E. R. Zell, T. A. Kenyon, and I. M. Onorato Risk Factors for Positive Mantoux Tuberculin Skin Tests in Children in San Diego, California: Evidence for Boosting and Possible Foodborne Transmission Pediatrics, August 1, 2001; 108(2): 305 - 310. [Abstract] [Full Text] [PDF]

				P. M. Small and P. I. Fujiwara Management of Tuberculosis in the United States N. Engl. J. Med., July 19, 2001; 345(3): 189 - 200. [Full Text] [PDF]

				K. A. Wendel, K. S. Alwood, R. Gachuhi, R. E. Chaisson, W. R. Bishai, and T. R. Sterling Paradoxical Worsening of Tuberculosis in HIV-Infected Persons Chest, July 1, 2001; 120(1): 193 - 197. [Abstract] [Full Text] [PDF]

				P. Escalante, E. A. Graviss, D. E. Griffith, J. M. Musser, and R. J. Awe Treatment of Isoniazid-Resistant Tuberculosis in Southeastern Texas Chest, June 1, 2001; 119(6): 1730 - 1736. [Abstract] [Full Text] [PDF]

				P Ormerod Respiratory diseases in pregnancy {bullet} 3: Tuberculosis in pregnancy and the puerperium Thorax, June 1, 2001; 56(6): 494 - 499. [Full Text]